Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA

Summary

ARTemIS-Eso is a phase I-II, three-level, open-label trial with a dose-expansion cohort at recommended schedule in both esophageal cancer histological groups (squamous cell carcinoma and adenocarcinoma) of RCT and ImT administered prior to surgery.

Timeline

Start

2017-07-20

Primary completion

2017-12-11

Completion

2017-12-11

Outcome

Outcome not reported

Stopped: “Suspended collaboration with the company providing the study drug”

Drugs

Indications